Tags

Type your tag names separated by a space and hit enter

[Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
Zhongguo Dang Dai Er Ke Za Zhi. 2008 Aug; 10(4):471-4.ZD

Abstract

OBJECTIVE

Methylphenidate is recommended as a first-line modality for treating attention deficit hyperactivity disorder (ADHD). In the past, immediate release methylphenidate (IR-MPH) was used for ADHD. Now oral osmotic-methylphenidate (OROS-MPH) is used for ADHD in China. This study was designed to investigate the efficacy and safety of OROS-MPH for treatment of ADHD in children.

METHODS

Ninety-nine children with ADHD were randomly administered with OROS-MPH (18 mg/time, once daily) and IR-MPH (5 mg/ time, twice or three times per day). After 6 weeks of treatment, the therapeutic effects were evaluated by the SNAP-IV and the IVA-CPT.

RESULTS

Fifty patients completed the 6-week treatment. The effective rate (83.3% vs 75%) and the complete remission rate (44% vs 25%) in the OROS-MPH treatment group were higher than that in the IR-MPH treatment group. There were statistically significant differences in the SNAP-IV and IVA-CPT scores before and after treatment in the two groups (P<0.01). The two groups had a similar incidence of side effects during treatment.

CONCLUSIONS

OROS-MPH for the treatment of ADHD is effective and safe in children, and its once-daily administration is more convenient.

Authors+Show Affiliations

Department of Developmental Pediatrics, Shengjing Hospital, China Medical University, Shenyang 110004, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Randomized Controlled Trial

Language

chi

PubMed ID

18706164

Citation

Pan, Xue-Xia, et al. "[Effectiveness of Oral Osmotic-methylphenidate in Treatment of Attention Deficit Hyperactivity Disorder in Children]." Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics, vol. 10, no. 4, 2008, pp. 471-4.
Pan XX, Ma HW, Wan B, et al. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2008;10(4):471-4.
Pan, X. X., Ma, H. W., Wan, B., & Dai, X. M. (2008). [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children]. Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics, 10(4), 471-4.
Pan XX, et al. [Effectiveness of Oral Osmotic-methylphenidate in Treatment of Attention Deficit Hyperactivity Disorder in Children]. Zhongguo Dang Dai Er Ke Za Zhi. 2008;10(4):471-4. PubMed PMID: 18706164.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children]. AU - Pan,Xue-Xia, AU - Ma,Hong-Wei, AU - Wan,Bin, AU - Dai,Xiao-Mei, PY - 2008/8/19/pubmed PY - 2008/10/15/medline PY - 2008/8/19/entrez SP - 471 EP - 4 JF - Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics JO - Zhongguo Dang Dai Er Ke Za Zhi VL - 10 IS - 4 N2 - OBJECTIVE: Methylphenidate is recommended as a first-line modality for treating attention deficit hyperactivity disorder (ADHD). In the past, immediate release methylphenidate (IR-MPH) was used for ADHD. Now oral osmotic-methylphenidate (OROS-MPH) is used for ADHD in China. This study was designed to investigate the efficacy and safety of OROS-MPH for treatment of ADHD in children. METHODS: Ninety-nine children with ADHD were randomly administered with OROS-MPH (18 mg/time, once daily) and IR-MPH (5 mg/ time, twice or three times per day). After 6 weeks of treatment, the therapeutic effects were evaluated by the SNAP-IV and the IVA-CPT. RESULTS: Fifty patients completed the 6-week treatment. The effective rate (83.3% vs 75%) and the complete remission rate (44% vs 25%) in the OROS-MPH treatment group were higher than that in the IR-MPH treatment group. There were statistically significant differences in the SNAP-IV and IVA-CPT scores before and after treatment in the two groups (P<0.01). The two groups had a similar incidence of side effects during treatment. CONCLUSIONS: OROS-MPH for the treatment of ADHD is effective and safe in children, and its once-daily administration is more convenient. SN - 1008-8830 UR - https://www.unboundmedicine.com/medline/citation/18706164/[Effectiveness_of_oral_osmotic_methylphenidate_in_treatment_of_attention_deficit_hyperactivity_disorder_in_children]_ L2 - http://www.diseaseinfosearch.org/result/659 DB - PRIME DP - Unbound Medicine ER -